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The prognosis of COVID-19 infection is poor once it develops to acute respiratory distress syndrome (ARDS) or
sepsis. Patients with COVID-19 who are in critical status require mechanical ventilation or extracorporeal mem-
brane oxygenation (ECMO) and treatment in the intensive care unit (ICU); however, indications and correspond-
ing management depend on critical care resources. Respiratory management consists of conventional oxygen
therapy, nasal high flow therapy, non-invasive positive pressure ventilation (NPPV), invasive positive pressure
ventilation (IPPV) and ECMO. Because ARDS due to COVID-19 has a different pathophysiology than conven-
tional ARDS and it rapidly worsens, indicating the need for infection management, immediate respiratory treat-
ments such as intubation or ECMO should be performed to achieve satisfactory outcomes. Furthermore, as anti-
viral agents for COVID-19 have not been approved yet, the crucial treatment for critically ill patients due to
COVID-19 is to control virustatic status, cytokine storm, and immonothrombosis. Lemdesivir, steroids, nafamostat
and anticoagulants could be promising pharmacologic efficiency. Continuous hemodiafiltration with cytokine-
adsorbing hemofilter by eliminating cytokines could also affect prognosis. In our ICU, 14 patients required critical
care management due to COVID-19 pneumoniae; mortality was 21% and none of them required aggressive ther-
apy. Patients with IPPV tends to have longer ICU stay periods compared to those with other respiratory support.
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Figure 1. The number of patients with ongoing ECMO due to COVID-19 from February 
to October, 2020 in Japan (a). The number of patients with ongoing invasive positive pres-
sure ventilation (IPPV) from February to October, 2020 in Japan (b).




19対策 ECMOnetが 2020年 2月中旬に COVID-19
重症患者に対する 24時間電話対応システム，症例数
のデータベース，intensive care unit（ICU）情報探











































（nasal high flow therapy：NHFT），非侵襲的人工呼












Table　1.　The management of V-V ECMO in our ICU.
Oxygenator Terumo LX
Centrifugal pump Terumo SL
Pump controller apparatus Terumo SP-101
Catheter (arterial side) Right internal jugular vein (Terumo CX EB16 ALX)
Catheter (venous side) Right femoral vein-atrium (Terumo CX EB21 LVX)
Blood flow rate 3.0-4.0 L/min
Sweep gas 3.0-4.0 L/min, FiO2 1.0
Arterial gas PO2 500mHg, CO2 40-45 mmHg, SO2 100%
Heat exchanger 36-36.5℃
Anticoagulant APTT 60-80 sec, ACT 180 sec
Terumo LX, Capiox® LX; Terumo SL, Capiox® SL; Terumo SP-101, Capiox® SP-101; 
FiO2, fraction of inspiratory oxygen; PO2, partial pressure of oxygen; PCO2, partial 
pressure of carbon dioxide; SO2, oxygen saturation APTT, activated partial throm-
boplastin time; ACT, activated clotting time.
14 cmH2O）設定で，腹臥位換気を行う重症 ARDS
の治療に準ずるとされている１０）～１３）．米国国立衛生研
究所（National Institutes of Health：NIH）のガイド
ラインでは，低 1回換気量（4～8 mL）（A I），プラ











venovenous ECMO（V-V ECMO）を 導 入 す る．

































































40 kg以上の小児には，投与初日に 200 mg，投与 2

























開発された薬剤で，severe acute respiratory syn-











































































































































Table　2.　Characteristics of patients with COVID-19 in Emergency ICU.




















70 M Pneumoniae COPD, post 
PCI, DCM
10 Y NPPV N N S  3
66 M TBI Unknown 17 Y COT N N D  1
45 M Pneumoniae DCM 15 Y V N Y D  2
52 M ADHF HT, asthma  9 Y COT N N S  5
54 M ARDS DM  5 Y V N N S 18
71 M Pneumoniae None  5 Y COT N N S  5
58 M Pneumoniae CRF on HD, 
DM
19 Y NHFT N HD S  5
66 M Pneumoniae DM  5 Y NHFT N N S  3
66 M Pneumoniae GRF on HD, 
ASO, AP, post 
MVR
14 Y COT N HD S  3
73 F ARDS DM 22 Y V Y Y S 47
66 M ARDS GRF on HD, 
ASO, AP, post 
MVR
21 Y V N N S 55
44 M ARDS None  2 Y NHFT N N S  5
86 F PCAS Dementia 41 Y V N N D 11
59 M ARDS Post-renal 
transplant
15 Y V N N S 10
APACHE II, Acute Physiology and Chronic Health Evaluation II; Y/N, yes/no; ECMO, extracorporeal membrane oxygenation; 
CHDF, continuous hemodiafiltration; HD, hemodialysis; ICU, intensive care unit; S/D, survivor/dead; COPD, chronic obstructive 
pulmonary disease; PCI, percutaneous coronary intervention; DCM, dilated cardiomyopathy; NPPV, non-invasive positive pressure 
ventilation; TBI, traumatic brain injury; COT, conventional oxygen therapy; ADHF, acute decompensated heart failure; HT, hyper-
tension; ARDS, acute respiratory distress syndrome; DM, diabetes mellitus; CRF, chronic renal failure; NHFT, nasal high flow ther-





























gen therapy：COT）4 例，NPPV 1 例，NHFT 3
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